WallStSmart

Capital One Financial Corporation (COF)vsStryker Corporation (SYK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Capital One Financial Corporation generates 44% more annual revenue ($36.31B vs $25.27B). SYK leads profitability with a 13.2% profit margin vs 8.9%. COF appears more attractively valued with a PEG of 0.20. COF earns a higher WallStSmart Score of 65/100 (C+).

COF

Buy

65

out of 100

Grade: C+

Growth: 7.3Profit: 6.0Value: 5.7Quality: 5.0

SYK

Buy

59

out of 100

Grade: C

Growth: 6.0Profit: 7.0Value: 4.7Quality: 6.0
Piotroski: 3/9Altman Z: 2.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for COF.

SYKOvervalued (-7.6%)

Margin of Safety

-7.6%

Fair Value

$265.38

Current Price

$285.47

$20.09 premium

UndervaluedFair: $265.38Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

COF6 strengths · Avg: 9.2/10
PEG RatioValuation
0.2010/10

Growing faster than its price suggests

Price/BookValuation
1.1x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
46.3%10/10

Revenue surging 46.3% year-over-year

Market CapQuality
$122.14B9/10

Large-cap with strong market position

Operating MarginProfitability
28.6%8/10

Strong operational efficiency at 28.6%

Free Cash FlowQuality
$5.47B8/10

Generating 5.5B in free cash flow

SYK1 strengths · Avg: 9.0/10
Market CapQuality
$112.69B9/10

Large-cap with strong market position

Areas to Watch

COF3 concerns · Avg: 2.3/10
Return on EquityProfitability
3.3%3/10

ROE of 3.3% — below average capital efficiency

P/E RatioValuation
59.3x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-4.3%2/10

Earnings declined 4.3%

SYK3 concerns · Avg: 3.7/10
P/E RatioValuation
34.0x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
2.6%4/10

2.6% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : COF

The strongest argument for COF centers on PEG Ratio, Price/Book, Revenue Growth. Revenue growth of 46.3% demonstrates continued momentum. PEG of 0.20 suggests the stock is reasonably priced for its growth.

Bull Case : SYK

The strongest argument for SYK centers on Market Cap. PEG of 1.39 suggests the stock is reasonably priced for its growth.

Bear Case : COF

The primary concerns for COF are Return on Equity, P/E Ratio, EPS Growth. A P/E of 59.3x leaves little room for execution misses.

Bear Case : SYK

The primary concerns for SYK are P/E Ratio, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

COF profiles as a hypergrowth stock while SYK is a value play — different risk/reward profiles.

COF carries more volatility with a beta of 1.05 — expect wider price swings.

COF is growing revenue faster at 46.3% — sustainability is the question.

COF generates stronger free cash flow (5.5B), providing more financial flexibility.

Bottom Line

COF scores higher overall (65/100 vs 59/100) and 46.3% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Capital One Financial Corporation

FINANCIAL SERVICES · CREDIT SERVICES · USA

Capital One Financial Corporation is an American bank holding company specializing in credit cards, auto loans, banking, and savings accounts, headquartered in McLean, Virginia with operations primarily in the United States.

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

Want to dig deeper into these stocks?